Long-Term Data Shows Feasibility of Adjuvant Trials in Prostate Cancer

April 3, 2017

This video examines long-term findings from a trial that tested ADT alone vs ADT plus chemotherapy as adjuvant therapy for patients with high-risk prostate cancer, including some surprising results and important takeaways.

In this video, L. Michael Glodé, MD, discusses long-term findings from a trial that tested 2 years of androgen-deprivation therapy (ADT) vs 2 years of ADT plus mitoxantrone and prednisone following radical prostatectomy in patients with high-risk prostate cancer. Glodé highlights some of the surprising results and important takeaways.

The trial, which began accrual in 1999, included 961 eligible patients but was stopped early due to a significant increase in cases of acute myeloid leukemia in the experimental arm. The 10-year overall survival rate was similar between the two groups (87% with ADT alone vs 86% with ADT plus chemotherapy).

Results of the study (abstract 2) were presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida.